Dr. Trevor D. Lohrey is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents & innovations group. Trevor’s practice centers on the prosecution of patents relating to pharmaceuticals, life sciences, and other matters involving state-of-the-art chemical technologies.
Prior to joining the firm, Trevor accumulated a wide breadth of experience in the chemical and physical sciences over nearly a decade of academic research. His scientific training was conducted at institutions including the California Institute of Technology; the University of California, Berkeley; and Lawrence Berkeley National Laboratory. Trevor’s technical experience is embodied in his co-authorship of over 40 peer-reviewed primary research articles.
Dr. Trevor D. Lohrey is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents & innovations group. Trevor’s practice centers on the prosecution of patents relating to pharmaceuticals, life sciences, and other matters involving state-of-the-art chemical technologies.
Prior to joining the firm, Trevor accumulated a wide breadth of experience in the chemical and physical sciences over nearly a decade of academic research. His scientific training was conducted at institutions including the California Institute of Technology; the University of California, Berkeley; and Lawrence Berkeley National Laboratory. Trevor’s technical experience is embodied in his co-authorship of over 40 peer-reviewed primary research articles.
- Postdoctoral Scholar, California Institute of Technology
- Ph.D., Chemistry, University of California, Berkeley
- B.A., Chemistry, Reed College
- U.S. Patent and Trademark Office
- Postdoctoral Scholar, California Institute of Technology
- Ph.D., Chemistry, University of California, Berkeley
- B.A., Chemistry, Reed College
- U.S. Patent and Trademark Office
Select Publications
- Co-author with A.Q. Cusumano, W.A. Goddard III, and B.M. Stoltz, “Identifying the Imperative Role of Metal–Olefin Interactions in Catalytic C–O Reductive Elimination from Nickel(II),” 11(16) ACS Catalysis 10208-10222, 2021
- Co-author with G. Rao, D.W. Small, E.T. Ouellette, R.G. Bergman, R.D. Britt, and J. Arnold, “Electronic Structures of Rhenium(II) β-Diketiminates Probed by EPR Spectroscopy: Direct Comparison of an Acceptor-Free Complex to Its Dinitrogen, Isocyanide, and Carbon Monoxide Adducts,” 142(32) Journal of the American Chemical Society 13805-13813, 2020
- Co-author with M.A. Boreen, G. Rao, R.D. Britt, L. Maron, and J. Arnold, “A Uranium Tri-Rhenium Triple Inverse Sandwich Compound,” 141(13) Journal of the American Chemical Society 5144-5148, 2019
- Co-author with L. Maron, R.G. Bergman, and J. Arnold, “Heterotetrametallic Re–Zn–Zn–Re Complex Generated by an Anionic Rhenium(I) β-Diketiminate,” 141(2) Journal of the American Chemical Society 800-804, 2019
- Co-author with R.G. Bergman and J. Arnold, “Olefin-Supported Rhenium(III) Terminal Oxo Complexes Generated by Nucleophilic Addition to a Cyclopentadienyl Ligand,” 56(45) Angewandte Chemie International Edition 14241-14245, 2017
Select Publications
- Co-author with A.Q. Cusumano, W.A. Goddard III, and B.M. Stoltz, “Identifying the Imperative Role of Metal–Olefin Interactions in Catalytic C–O Reductive Elimination from Nickel(II),” 11(16) ACS Catalysis 10208-10222, 2021
- Co-author with G. Rao, D.W. Small, E.T. Ouellette, R.G. Bergman, R.D. Britt, and J. Arnold, “Electronic Structures of Rhenium(II) β-Diketiminates Probed by EPR Spectroscopy: Direct Comparison of an Acceptor-Free Complex to Its Dinitrogen, Isocyanide, and Carbon Monoxide Adducts,” 142(32) Journal of the American Chemical Society 13805-13813, 2020
- Co-author with M.A. Boreen, G. Rao, R.D. Britt, L. Maron, and J. Arnold, “A Uranium Tri-Rhenium Triple Inverse Sandwich Compound,” 141(13) Journal of the American Chemical Society 5144-5148, 2019
- Co-author with L. Maron, R.G. Bergman, and J. Arnold, “Heterotetrametallic Re–Zn–Zn–Re Complex Generated by an Anionic Rhenium(I) β-Diketiminate,” 141(2) Journal of the American Chemical Society 800-804, 2019
- Co-author with R.G. Bergman and J. Arnold, “Olefin-Supported Rhenium(III) Terminal Oxo Complexes Generated by Nucleophilic Addition to a Cyclopentadienyl Ligand,” 56(45) Angewandte Chemie International Edition 14241-14245, 2017
In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.
- Privacy Policy
- Terms of Use
- Accessibility